Expertise in
50
conditions

Dr. Wahid T. Hanna

Hematology
Association Of University Radioloigsts
1926 Alcoa Hwy Bldg F, 
Knoxville, TN 
Accepting New Patients
Offers Telehealth
Expertise in
50
conditions
Association Of University Radioloigsts
1926 Alcoa Hwy Bldg F, 
Knoxville, TN 

Overview

Wahid Hanna is a Hematologist practicing medicine in Knoxville, Tennessee.

Dr. Hanna is highly rated in 50 conditions, according to our data. His clinical expertise encompasses Non-Hodgkin Lymphoma, B-Cell Lymphoma, Thrombocytopenia, Immune Thrombocytopenic Purpura (ITP), and Bone Marrow Aspiration.

He is actively involved in clinical research, co-authoring 6 peer reviewed articles and participating in 13 clinical trials. Dr. Hanna is currently accepting new patients.

Specialties

Hematology

Licenses

Internal Medicine in TN

Hospital Affiliations

Fort Sanders Regional Medical Center
Physicians Regional Medical Center
Blount Memorial Hospital
University Health System, Inc
Parkwest Medical Center

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Farm Bureau Health Plans
  • HMO
  • MEDICARE MAPD
  • MEDICARE PDP
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Kaiser Permanente
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER MEDICARE
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 12 Less Insurance Carriers -

Locations

Association of University Radioloigsts
1926 Alcoa Hwy Bldg F, Knoxville, TN 37920

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

13 Clinical Trials

Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy
Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy
Enrollment Status: Active_not_recruiting
Publish Date: August 10, 2026
Intervention Type: Procedure, Drug, Other
Study Drug: Pazopanib Hydrochloride
Study Phase: Phase 3
A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation
A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation
Enrollment Status: Active_not_recruiting
Publish Date: July 31, 2026
Intervention Type: Other, Drug
Study Drugs: Temozolomide, Veliparib
Study Phase: Phase 2/Phase 3
ATHN 9: A Natural History Cohort Study of the Safety, Effectiveness, and Practice of Treatment for People With Severe Von Willebrand Disease (VWD)
ATHN 9: A Natural History Cohort Study of the Safety, Effectiveness, and Practice of Treatment for People With Severe Von Willebrand Disease (VWD)
Enrollment Status: Completed
Publish Date: July 13, 2026
Phase 3, Open-Label, 4-Cohort Study of Nogapendekin Alfa Inbakicept in Combination With Current Standard of Care as First-Line Treatment for Patients With Advanced or Metastatic Non-Small Cell Lung Cancer
Phase 3, Open-Label, 4-Cohort Study of Nogapendekin Alfa Inbakicept in Combination With Current Standard of Care as First-Line Treatment for Patients With Advanced or Metastatic Non-Small Cell Lung Cancer
Enrollment Status: Terminated
Publish Date: May 26, 2026
Intervention Type: Drug
Study Drugs: N-803+Pembrolizumab, N-803+Carboplatin+Nab-paclitaxel+Pembrolizumab, N-803+Cisplatin or Carboplatin+Pembrolizumab+Pemetrexed, Pembrolizumab, Carboplatin+Nab-paclitaxel or Paclitaxel+Pembrolizumab, Cisplatin or Carboplatin+Pembrolizumab+Pemetrexed
Study Phase: Phase 3
A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients With Stage 0-III Colon or Rectal Cancer, Phase III - Preventing Adenomas of the Colon With Eflornithine and Sulindac (PACES)
A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients With Stage 0-III Colon or Rectal Cancer, Phase III - Preventing Adenomas of the Colon With Eflornithine and Sulindac (PACES)
Enrollment Status: Active_not_recruiting
Publish Date: April 02, 2026
Intervention Type: Drug
Study Phase: Phase 3
A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 With Androgen Deprivation Therapy + Bicalutamide in Patients With Newly Diagnosed Metastatic Sensitive Prostate Cancer
A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 With Androgen Deprivation Therapy + Bicalutamide in Patients With Newly Diagnosed Metastatic Sensitive Prostate Cancer
Enrollment Status: Completed
Publish Date: December 31, 2025
Intervention Type: Drug
Study Drugs: TAK-700, Bicalutamide
Study Phase: Phase 3
Phase 1b/2a Safety and Pharmacokinetic Study of G1T28 in Patients With Previously Treated Extensive Stage Small Cell Lung Cancer (SCLC) Receiving Topotecan Chemotherapy
Phase 1b/2a Safety and Pharmacokinetic Study of G1T28 in Patients With Previously Treated Extensive Stage Small Cell Lung Cancer (SCLC) Receiving Topotecan Chemotherapy
Enrollment Status: Completed
Publish Date: September 25, 2025
Intervention Type: Drug
Study Drugs: Trilaciclib, Topotecan
Study Phase: Phase 1/Phase 2
A Phase II Study of RRx-001 in Platinum Refractory/Resistant Small Cell Carcinoma, EGFR TKI Resistant EGFR+ T790M Negative Non-Small Cell Lung Cancer, High Grade Neuroendocrine Tumors and Resistant/Refractory Ovarian Cancer Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)
A Phase II Study of RRx-001 in Platinum Refractory/Resistant Small Cell Carcinoma, EGFR TKI Resistant EGFR+ T790M Negative Non-Small Cell Lung Cancer, High Grade Neuroendocrine Tumors and Resistant/Refractory Ovarian Cancer Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)
Enrollment Status: Completed
Publish Date: March 17, 2025
Intervention Type: Drug
Study Drugs: RRx-001, Cisplatin, Etoposide, Carboplatin, Irinotecan, Vinorelbine, Doxil, Gemcitabine, Taxane, Paclitaxel, Nab-Paclitaxel, Pemetrexed
Study Phase: Phase 2
A Phase III, Multicenter, Randomized, Double Blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Canakinumab Versus Placebo as Adjuvant Therapy in Adult Subjects With Stages AJCC/UICC v. 8 II -IIIA and IIIB (T>5cm N2) Completely Resected (R0) Non-small Cell Lung Cancer (NSCLC)
A Phase III, Multicenter, Randomized, Double Blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Canakinumab Versus Placebo as Adjuvant Therapy in Adult Subjects With Stages AJCC/UICC v. 8 II -IIIA and IIIB (T>5cm N2) Completely Resected (R0) Non-small Cell Lung Cancer (NSCLC)
Enrollment Status: Terminated
Publish Date: October 09, 2024
Intervention Type: Drug
Study Drug: Canakinumab
Study Phase: Phase 3
A Phase 3 Randomized Double-blind, Controlled Study of ICT-107 With Maintenance Temozolomide (TMZ) in Newly Diagnosed Glioblastoma Following Resection and Concomitant TMZ Chemoradiotherapy
A Phase 3 Randomized Double-blind, Controlled Study of ICT-107 With Maintenance Temozolomide (TMZ) in Newly Diagnosed Glioblastoma Following Resection and Concomitant TMZ Chemoradiotherapy
Enrollment Status: Suspended
Publish Date: April 03, 2024
Intervention Type: Biological
Study Phase: Phase 3
View 9 Less Clinical Trials

6 Total Publications

Parsaclisib for the treatment of primary autoimmune hemolytic anemia: Results from a phase 2, open-label study.
Parsaclisib for the treatment of primary autoimmune hemolytic anemia: Results from a phase 2, open-label study.
Journal: American journal of hematology
Published: May 02, 2024
Similar Doctors
Expertise in
26
conditions
Dr. Haydar A. Frangoul
Hematology | Oncology
Expertise in
26
conditions
Dr. Haydar A. Frangoul
Hematology | Oncology
Referral may be required

TriStar Medical Group Children's Specialists - West Clinch Ave

2018 Clinch Ave, 
Knoxville, TN 
 (5.0 miles away)
Languages Spoken:
English, Arabic
See accepted insurances
Accepting New Patients

Haydar Frangoul is a Hematologist and an Oncologist practicing medicine in Knoxville, Tennessee. Dr. Frangoul is highly rated in 26 conditions, according to our data. His clinical expertise encompasses Beta Thalassemia, Congenital Hemolytic Anemia, Hemoglobinopathy, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Frangoul is currently accepting new patients.

Expertise in
20
conditions
Expertise in
20
conditions
Referral may be required

University Gynecologic Oncology

1926 Alcoa Hwy, 
Knoxville, TN 
 (4.8 miles away)
865-305-6055
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Albert Quiery is a Hematologist practicing medicine in Knoxville, Tennessee. Dr. Quiery is highly rated in 20 conditions, according to our data. His clinical expertise encompasses Sickle Cell Disease, Schnitzler Syndrome, Chronic Myelogenous Leukemia (CML), Philadelphia-Negative Chronic Myeloid Leukemia, and Bone Marrow Aspiration. Dr. Quiery is currently accepting new patients.

Expertise in
23
conditions
Expertise in
23
conditions
Referral may be required

Tennessee Cancer Specialists PLLC

1415 Old Weisgarber Rd Ste 200, 
Knoxville, TN 
 (8.9 miles away)
865-934-5800
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

David Aljadir is a Hematologist practicing medicine in Knoxville, Tennessee. Dr. Aljadir is highly rated in 23 conditions, according to our data. His clinical expertise encompasses Non-Hodgkin Lymphoma, Follicular Lymphoma, Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma, and Bone Marrow Aspiration. Dr. Aljadir is currently accepting new patients.

Frequently Asked Questions about Dr. Wahid T. Hanna

How do I make an appointment with Dr. Wahid T. Hanna?

You can book an appointment with Dr. Wahid T. Hanna by calling their office at 865-544-9171. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Wahid T. Hanna a top-rated expert for Non-Hodgkin Lymphoma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Wahid T. Hanna is classified as an Distinguished expert for Non-Hodgkin Lymphoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Wahid T. Hanna specialize in?

While Dr. Wahid T. Hanna is a Hematology, they have specific expertise in Non-Hodgkin Lymphoma, B-Cell Lymphoma, and Thrombocytopenia. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Wahid T. Hanna participate in research or clinical trials?

Yes. Dr. Wahid T. Hanna has published 6 articles and abstracts on conditions like Non-Hodgkin Lymphoma. You can view a list of Dr. Wahid T. Hanna's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Wahid T. Hanna accept my insurance?

Dr. Wahid T. Hanna accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 865-544-9171 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Hanna's expertise for a condition
ConditionClose
    View All 16 Distinguished Conditions
    View All 34 Advanced Conditions
    View All 62 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile